Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-04-22
2008-04-22
Anderson, Rebecca (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S429000
Reexamination Certificate
active
07361680
ABSTRACT:
The present invention provides novel indole derivatives useful to inhibit cancer or sensitize cancer cells to chemotherapeutic agents, radiation or other anti-cancer treatments.
REFERENCES:
patent: 3053255 (1962-09-01), Meyer
patent: 3710795 (1973-01-01), Higuchi et al.
patent: 3843480 (1974-10-01), Dreher
patent: 3843681 (1974-10-01), Demerson et al.
patent: 3939178 (1976-02-01), Demerson et al.
patent: 3948254 (1976-04-01), Zaffaroni
patent: 3948262 (1976-04-01), Zaffaroni
patent: 3974179 (1976-08-01), Demerson et al.
patent: 3993073 (1976-11-01), Zaffaroni
patent: 4041169 (1977-08-01), Demerson et al.
patent: 4179503 (1979-12-01), Asselin et al.
patent: 4310509 (1982-01-01), Berglund et al.
patent: 4337760 (1982-07-01), Rubin
patent: 4460562 (1984-07-01), Keith et al.
patent: 4466953 (1984-08-01), Keith et al.
patent: 4482534 (1984-11-01), Blank
patent: 4485097 (1984-11-01), Bell
patent: 4505891 (1985-03-01), Ito
patent: 4533540 (1985-08-01), Blank
patent: 4542012 (1985-09-01), Dell
patent: 4542013 (1985-09-01), Keith et al.
patent: 4560555 (1985-12-01), Snider
patent: 4585877 (1986-04-01), Demerson et al.
patent: 4597961 (1986-07-01), Etscorn
patent: 4608249 (1986-08-01), Otsuka
patent: 4686213 (1987-08-01), Ferdinandi et al.
patent: 4748252 (1988-05-01), Ferdinandi et al.
patent: 4806356 (1989-02-01), Shaw
patent: 4940587 (1990-07-01), Jenkins et al.
patent: 5561151 (1996-10-01), Young et al.
patent: 5599946 (1997-02-01), Vincenzo et al.
patent: 5776967 (1998-07-01), Kreft et al.
patent: 5780435 (1998-07-01), Garnick et al.
patent: 5811558 (1998-09-01), Adger et al.
patent: 5824699 (1998-10-01), Kreft et al.
patent: 5939455 (1999-08-01), Rephaeli
patent: 5955504 (1999-09-01), Wechter et al.
patent: 5968974 (1999-10-01), Kargman et al.
patent: 5981592 (1999-11-01), Wechter et al.
patent: 6066741 (2000-05-01), Vigano' et al.
patent: 6110955 (2000-08-01), Nudelman et al.
patent: 6160018 (2000-12-01), Wechter et al.
patent: 6300313 (2001-10-01), Engel et al.
patent: 6545034 (2003-04-01), Carson et al.
patent: 6552055 (2003-04-01), Spiegelman et al.
patent: 7105560 (2006-09-01), Carson et al.
patent: 7105561 (2006-09-01), Carson et al.
patent: 7129262 (2006-10-01), Carson et al.
patent: 7151100 (2006-12-01), Carson et al.
patent: 7189752 (2007-03-01), Carson et al.
patent: 7211599 (2007-05-01), Carson et al.
patent: 2002/0042375 (2002-04-01), Heimbrook et al.
patent: 2003/0004142 (2003-01-01), Prior et al.
patent: 2003/0004143 (2003-01-01), Prior et al.
patent: 2005/0239752 (2005-10-01), Carson et al.
patent: 2007/0111950 (2007-05-01), Carson et al.
patent: 1999520989 (2000-02-01), None
patent: 1299577 (1992-04-01), None
patent: 2226340 (1973-03-01), None
patent: 0289262 (1986-11-01), None
patent: 0289262 (1988-11-01), None
patent: 1436893 (1976-05-01), None
patent: WO-96/28148 (1996-09-01), None
patent: WO-9628148 (1996-09-01), None
patent: WO-9748391 (1997-12-01), None
patent: WO-98/09603 (1998-03-01), None
patent: WO-9809603 (1998-03-01), None
patent: WO-98/18490 (1998-05-01), None
patent: WO-98/40078 (1998-09-01), None
patent: WO-00/02555 (2000-01-01), None
patent: WO-00/13410 (2000-03-01), None
patent: WO-0106990 (2001-02-01), None
patent: WO01/014448 (2001-03-01), None
patent: WO-02/02125 (2002-01-01), None
patent: WO-0212188 (2002-02-01), None
1991 New Drugs, (Sep. 1991),42-60.
Drug Facts and Comparisons, 1995 Edition, Wolters Kluwer Co.,(1995),2775-2789.
The Merck Index, Thirteenth Edition, Budavari, S., et al., (eds.), Merck & Co., Inc., Rahway, N.J., “Etodolac, Entry No. 3905 ”,(1990),p. 685.
In: Remington's Pharmaceutical Sciences, Eighteenth Edition, Gennaro, A.R., (ed.), Mack Publishing Company, Easton, PA,(1990),pp. 1115-1122.
“1991 New Drugs”,US Pharmacist, 61, Pages not cited are advertisements,(Sep. 1991),35-40, 42, 44,46, 48-50, 52, 57-58, 60, 62, 64.
“International Search Report for PCT/US2004/032185”, 2005.
Abramson, S. B., et al., “The Mechanisms of Action of Nonsteroidal Antiinflammatory Drugs”,Arthritis&Rheumatism, 32 (1), (Jan. 1989),1-9.
Alexanian, R. , et al., “The Treatment of Multiple Myeloma”,The New England Journal of Medicine, 330 (7), (Feb. 17, 1994),484-489.
Barlogie, B , “Prognostic Factors with High-Dose Melphalan for Refractory Multiple Myeloma.”Blood, 72(6), (Dec. 1988),2015-2019.
Bataille, R , et al., “Multiple Myeloma”,New England Journal of Medicine, 336, (1997),1657-1664.
Becker-Scharfenkamp, U. , et al., “Evaluation of the Stereoselective Metabolism of the Chiral Analgesic Drug Etodolac by High-Performance Liquid Chromatography”,Journal of Chromatography, 621 (2), (Nov. 24, 1993),pp. 199-207.
Bellosillo, Beatriz , et al., “Aspirin and Salicylate Induce Apoptosis and Activation of Caspases in B-Cell Chronic Lymphocytic Leukemia Cells”,Blood, 92 (4), (Aug. 15, 1998),1406-1414.
Berendes, U. , et al., “Simultaneous Determination of the Phase II Metabolites of the Non Steriodal Anti-Inflammatory Drug Etodolac in Human Urine”,Enantiomer, 1, Abstract Only, Chemical Abstracts, Abstract No. 126:207064q,(1996),415-422.
Berendes, U. , et al., “Simultaneous Determination of the Phase II Metabolites of the Non Steroidal Anti-Inflammatory Drug Etodolac”,Chemical Abstracts, 126, Abstract No. 207064,(Apr. 21, 1997),p. 9.
Berkow, et al.,The Merck Manual of Medical Information, Merck Research Laboratories,(1997),p. 765-66 and 779-80.
Brenna, E. , et al.,Tetrahedron, vol. 53 (52), (1997),17769-17780.
Brenna, Elisabetta , et al., “New Enzymatic and Chemical Approaches to Enantiopur Etodolac”,Tetrahedron, vol. 53, No. 52, (1997),17769-17780.
Brenna, E. , et al., “New Enzymatic and Chemical Approaches to Enantiopure Etodolac”,Tetrahedron, 53, (1997),17769-17780.
Brocks, D. R., et al., “Etodolac Clinical Pharmacokinetics”,Clinical Pharmacokinetics, 26(4), (1994),pp. 259-274.
Carson, D. A., et al., “Oral Antilymphocyte Activity and Induction of Apoptosis by 2-chloro-2′-arabino-fluoro-2′-deoxyadenosine”,Proceedings of the National Academy of Sciences USA, 89 (7), (Apr. 1, 1992),2970-2974.
Chinetti, G. , et al., “Activation of Proliferator-activated Receptors alpha and Υ Induces Apoptosis of Human Monocyte-derived Macrophages”,Journal of Biological Chemistry, 273 (40), (Oct. 2, 1998),25573-25580.
Cunningham, D , et al., “High-dose Melphalan for Multiple Myeloma: Long-term Follow-up Data”,Journal of Clinical Oncology, 12, (1994),764-768.
Demerson, C. A., et al., “Etodolic Acid and Related Compounds. Chemistry and Antiiinflammatory Actions of Some Potent Di- and Trisubstituted 1,3,4,9-Tetrahydropyrano[3,4-b]indole-1-acetic Acids”,Journal of Medicinal Chemistry, 19 (3), (1976),pp. 391-395.
Demerson, C. A., et al., “Resolution of Etodolac and Antiinflammatory and Prostaglandin Synthetase Inhibiting Properties of the Enantiomers”,J. Med. Chem., 26 (12), (Dec. 1983),pp. 1778-1780.
Drachenberg, D. E., “Treatment of Prostate Cancer: Watchful Waiting, Radical Prostatectomy, and Cryoablation”,Seminars in Surgical Oncology, 18 (1), (Jan./Feb. 2000),pp. 37-44.
Duffy, C. P., et al., “Enhancement of Chemotherapeutic Drug Toxicity to Human Tumour Cells In Vitro by a Subset of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)”,European Journal of Cancer, 34 (8), (Jul. 1998),pp. 1250-1259.
Hahnfeld, L. E., et al., “Prostate Cancer”,The Medical Clinics of North America—The Aging Male Patient, 83 (5), (Sep. 1999),pp. 1231-1245.
Harousseau, J.L., et al., “Double-Intensive Therapy in High-Risk Multiple Myeloma”,Blood, 79 (11), (Jun. 1, 1992),pp. 2827-2833.
Heath, Clark W., “Nonsteroidal Antiinflammatory Drugs and Human Cancer”,American Cancer Society, vol. 74, No. 10, (Nov. 15, 1994),2885-2886.
Kamijo, T. , et al., “Induction of apoptosis by cyclooxygenase-2 inhibitors in prostate cancer cell lines”,Inte
Carson Dennis A.
Cottam Howard B.
Leoni Lorenzo M.
Anderson Rebecca
Barker Michael P.
Schwegman Lundberg & Woessner, P.A.
The Regents of the University of California
LandOfFree
Indole compounds useful for the treatment of cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Indole compounds useful for the treatment of cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Indole compounds useful for the treatment of cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2763107